Table 1.
List of selected proteins that were confidently quantified.
| Reference ID | Protein name | # of different peptides quantified | Average 18O/16O abundance ratio | Standard deviation |
|---|---|---|---|---|
| Proteins with significant changes in abundance following LPS administration | ||||
| NP_110381 | Serum amyloid A2 | 1 | 4.78 | |
| SAA_HUMAN | Serum amyloid A | 2 | 4.70 | 0.69 |
| CRP_HUMAN | C-reactive protein | 2 | 3.60 | 0.57 |
| NP_079050 | Hypothetical protein FLJ21294 | 1 | 3.52 | |
| XP_294574 | Similar to A-kinase anchor protein 8 | 2 | 3.45 | 0.71 |
| UTRO_HUMAN | Utrophin | 1 | 3.31 | |
| FAT2_HUMAN | Protocadherin Fat 2 | 1 | 3.29 | |
| CENF_HUMAN | CENP-F kinetochore protein | 1 | 2.98 | |
| NP_060887 | Soluble adenylyl cyclase | 1 | 2.74 | |
| XP_374705 | Similar to polycystic kidney disease 1-like 3 | 1 | 2.65 | |
| CAD5_HUMAN | Vascular endothelial-Cadherin | 1 | 2.50 | |
| VWF_HUMAN | Von Willebrand factor | 5 | 2.47 | 0.47 |
| PSD6_HUMAN | 26s proteasome non-ATPase regulatory subunit 6 | 1 | 2.47 | |
| PRTC_HUMAN | Vitamin K-dependent protein C | 1 | 2.33 | |
| XP_376649 | Hypothetical protein KIAA2005 | 1 | 2.16 | |
| MGA_HUMAN | Maltase-Glucoamylase | 1 | 2.15 | |
| NP_056467 | Hypothetical protein | 1 | 2.12 | |
| HGFL_HUMAN | Hepatocyte growth factor-like protein | 1 | 1.93 | |
| XP_040265 | Hypothetical protein KIAA0217 | 1 | 1.90 | |
| LBP_HUMAN | LPS-binding protein | 4 | 1.78 | 0.18 |
| A2GL_HUMAN | Leucine-rich alpha-2-glycoprotein | 6 | 1.71 | 0.18 |
| GFAP_HUMAN | Glial fibrillary acidic protein, Astrocyte | 1 | 0.37 | |
| OCTC_HUMAN | Peroxisomal carnitine octanoyltransferase | 1 | 0.39 | |
| HBB_HUMAN | Beta globin | 7 | 0.41 | 0.21 |
| CYA1_HUMAN | Brain adenylate cyclase 1 | 1 | 0.49 | |
|
Selected proteins with NO significant changes in abundance following LPS administration | ||||
| CO3_Human | Complement C3 | 137 | 1.01 | 0.18 |
| A2MG_HUMAN | Alpha-2-macroglobulin | 113 | 0.97 | 0.15 |
| TRFE_HUMAN | Serotransferrin | 74 | 0.97 | 0.16 |
| FIBB_HUMAN | Fibrinogen beta chain | 43 | 1.04 | 0.14 |
| CFAB_HUMAN | Complement factor B | 25 | 1.04 | 0.12 |
| PEDF_HUMAN | Pigment epithelium-derived factor | 10 | 1.05 | 0.17 |
| HEP2_HUMAN | Heparin cofactor II | 13 | 1.00 | 0.18 |
| ECM1_HUMAN | Extracellular matrix protein 1 | 7 | 1.02 | 0.15 |
| A2AP_HUMAN | Alpha-2-antiplasmin | 6 | 0.94 | 0.13 |
| TETN_HUMAN | Tetranectin | 5 | 0.96 | 0.14 |
| Q92954 | Megakaryocyte stimulating factor | 3 | 1.28 | 0.06 |
| ALS_HUMAN | Acid labile chain | 3 | 0.93 | 0.09 |
*
Abundance ratio > 1 indicates an increase in protein concentration following LPS administration. If the abundance ratios differs from 1.0 with more than 3-fold of standard deviation (0.23) from control experiment (either >1.69 or < 0.59), the proteins are considered to be with significant changes in abundance following LPS administration. Proteins with only one unique peptide detected were considered to be less confidently quantified than those proteins with multiple peptides detected.